A Guide To Ayurvedic Clinical Practice Pdf Download

[Keri Gamrath]

Ayurvedais based on the belief that health and wellness depend on a delicate balance between the mind, body, spirit, and environment. The main goal of ayurvedic medicine is to promote good health and prevent, not fight, disease. But treatments may be geared toward specific health problems.

These combine in the human body to form three life forces, or energies, called doshas. They control how your body works. They are vata dosha (space and air); pitta dosha (fire and water); and kapha dosha (water and earth).

Those who practice ayurveda believe this is the most powerful of all three doshas. It controls very basic body functions, like how cells divide. It also controls your mind, breathing, blood flow, heart function, and ability to get rid of waste through your intestines. Things that can disrupt it include eating again too soon after a meal, fear, grief, and staying up too late.

When you are out of balance, you can get overstimulated and have anxiety, phobias, and be forgetful. You can also be more likely to have conditions like asthma, heart disease, skin problems, and rheumatoid arthritis.

In ayurveda, like increases like. For this dosha (space and air), you can balance out too much vata by doing things that are grounding like meditation, massage, keeping a regular sleep and wake schedule, and eating warm, mild foods.

This energy controls your digestion, metabolism (how well you break down foods), and certain hormones that are linked to your appetite. Things that can disrupt pitta are eating sour or spicy foods, spending too much time in the sun, and missing meals.

Kapha dosha is thought to control muscle growth, body strength and stability, weight, and your immune system. Things that can disrupt kapha include daytime naps, eating too many sweet foods, and eating or drinking things that contain too much salt or water.

When out of balance, you can easily get fatigued, avoid taking on new projects, and be possessive, stubborn, and depressed. If you are kapha dominant, you may be more likely to develop asthma and other breathing disorders, cancer, diabetes, nausea after eating, and obesity.

To reduce excess kapha (earth and water) and be more balanced, you can increase the amount of fruits and vegetables in your diet, and do exercise that gets the blood flowing like jogging or sun salutations in yoga.

Try keeping a regular sleep/wake schedule and adopting better sleep hygiene. (Keep your bedroom quiet, at a comfortable temperature, and dark at bedtime. Keep laptops and phones out of the bedroom at night.)

You can incorporate many herbs used in ayurveda when cooking food. Before taking herbal supplements, check with your doctor to make sure they are safe and won't interact with any medications you are taking. Some of the most commonly used, and easy-to-access, herbs in ayurveda include:

What is an example of ayurvedic medicine? If you are a pitta person, whose constitution is made of fire, you should exercise during the coolest times of day, eat cooling foods, like salad, and avoid caffeine and alcohol, which increase your digestive fire.

The WHO benchmarks for the training of Ayurveda is an update of its previous version published in 2010. It defines the minimum requirement/criteria for establishing training of Ayurveda in WHO Member States. It provides the fundamental knowledge requirements for all those involved in practice and training of Ayurveda, including safety issues related to its clinical application and medicinal preparation. The document shall serve as a reference to national authorities to establish/strengthen regulatory standards to ensure qualified training and practice of Ayurveda. The document is aligned with the objectives of the WHO Traditional Medicine Strategy 2014-23. It reflects consensus arrived through established WHO processes from the community of practitioners in Ayurveda, health service providers, academics, health system managers, and regulators. The document provides information on types of training including training requirements for Ayurveda practitioners and associate Ayurveda service providers, presents the requirements on competency-based knowledge and skills for Ayurveda practitioners and associate Ayurveda providers, and provides content and structures for different training programmes.

Patients who are severely immunocompromised or have certain skin conditions, such as eczema, are at particular risk of uncontrolled viral spread, a severe manifestation of mpox that can be life-threatening.

Tecovirimat is a novel antiviral that was made available for treatment of certain patients with mpox under the CDC-held Expanded Access-Investigational New Drug (EA-IND) protocol during the global outbreak of mpox that began in 2022.

Data are not yet available on the effectiveness of tecovirimat in treating mpox infections in people. Based on the animal efficacy data that showed survival benefit over placebo in lethal animal models, it may be reasonable to anticipate tecovirimat may provide benefit in treating some people with disease caused by orthopoxviruses, including the virus that causes mpox. However, whether and how the efficacy in animals may translate to humans with active disease, the patients who might benefit from tecovirimat, and what specific clinical benefits might occur with tecovirimat are unknown currently. There are ongoing clinical trials to determine the efficacy and safety of tecovirimat in people with mpox.

The National Institute of Allergy and Infectious Disease is conducting the Study of Tecovirimat for Mpox (STOMP) clinical trial to assess the efficacy of tecovirimat. STOMP has an open-label TPOXX arm for patients who are severely immunocompromised, have certain active skin conditions or severe disease, for pregnant or lactating people and children under 18 years of age. All patients in this arm of the trial will receive oral TPOXX.

Data from this trial will help scientists learn which patients get the most benefit from this therapeutic and guide regulators who decide whether to approve its use for mpox. Patients should be informed about STOMP and encouraged to consider enrollment.

CDC holds an Expanded Access-Investigational New Drug (EA-IND) protocol that allows for the use of stockpiled tecovirimat to treat patients with mpox who meet EA-IND eligibility criteria. Tecovirimat is available orally or intravenously for certain patients with (or who are at high risk for) protracted or life-threatening illness, including severely immunocompromised patients, people with atopic dermatitis and other conditions affecting skin integrity, children and pregnant or breastfeeding adults.

Tecovirimat is typically the first therapeutic that should be considered if patients with mpox require more than supportive care. Brincidofovir and Vaccinia Immune Globulin (VIGIV) are additional therapeutics, available from the Strategic National Stockpile (SNS), that can be considered for treatment of mpox in certain patients who necessitate an additional or alternative treatment to tecovirimat. Cidofovir is a commercially available antiviral that has the same mechanism of action as brincidofovir and could also be considered. For patients with eye infections involving mpox, trifluridine ophthalmic solution might also be considered after consultation with ophthalmologists.

Decisions on whether and when to use these additional or alternative therapeutics must be made individually for each person and can depend on a variety of clinical and other parameters. Healthcare providers preferring a clinical consultation with CDC or who have patient management questions may contact the CDC during regular business hours at poxv...@cdc.gov and after hours via the CDC Emergency Operations Center [EOC] at (770) 488-7100.

Brincidofovir is a prodrug of cidofovir that is approved by the FDA [670 KB, 21 pages] for the treatment of human smallpox disease in adult and pediatric patients, including neonates. Data are not available on the effectiveness of brincidofovir in treating mpox virus infection in people. However, it has shown to be effective against orthopoxviruses in in vitro and animal studies. Brincidofovir should not be used simultaneously with cidofovir.

Nearly all patients who receive brincidofovir are severely immunocompromised and require brincidofovir in combination with tecovirimat. Brincidofovir should not be used simultaneously with cidofovir. Clinicians can switch patients between IV cidofovir and brincidofovir right away without a drug holiday.

VIGIV is licensed by FDA [196 KB, 18 pages] for the treatment of complications due to vaccinia vaccination. However, it is not approved for treatment of mpox. Therefore, CDC holds an expanded access IND protocol [581 KB, 24 pages] that allows the use of stockpiled VIGIV for the treatment of orthopoxviruses (including mpox) in an outbreak.

Data are not available on the effectiveness of VIGIV in treatment of mpox virus infection in people. Use of VIGIV has no proven benefit in the treatment of mpox and it is unknown whether a person with severe mpox infection will benefit from treatment with VIGIV. However, healthcare providers may consider its use in severe cases in which the development of a robust antibody response may be impaired.

VIGIV can be considered for prophylactic use in an exposed person with severe immunodeficiency in T-cell function for which smallpox or mpox vaccination following exposure to mpox virus is contraindicated. Patients who receive VIGIV typically are concomitantly receiving both tecovirimat and either brincidofovir or cidofovir.

VIGIV is available upon clinician request to CDC on a case-by-case basis. To request VIGIV, clinicians can contact the CDC Clinical Consultation Team by email (poxv...@cdc.gov) during business hours, or for urgent clinical situations, contact the CDC Emergency Operations Center (770-488-7100). Informed consent [293 KB, 6 pages] must be obtained prior to administration. The remaining VIGIV IND fillable forms will be provided to clinicians requesting VIGIV.

3a8082e126